tiprankstipranks
Japan Medical Dynamic Marketing, Inc. (JP:7600)
:7600
Japanese Market
Want to see JP:7600 full AI Analyst Report?

Japan Medical Dynamic Marketing, Inc. (7600) AI Stock Analysis

0 Followers

Top Page

JP:7600

Japan Medical Dynamic Marketing, Inc.

(7600)

Select Model
Select Model
Select Model
Neutral 54 (OpenAI - 5.2)
Rating:54Neutral
Price Target:
¥945.00
▲(94.05% Upside)
Action:Reiterated
Date:06/18/26
The score is held back primarily by deteriorating financial quality—especially sharply weaker cash generation and compressed margins—despite a still-manageable balance sheet. Technicals are a clear positive with strong upward price trends, but valuation is a headwind given the very high P/E and only modest dividend yield.
Positive Factors
Moderate Leverage
Moderate leverage and a large equity base provide financial flexibility to absorb operating volatility and fund business needs. Although debt has risen from 2024, current indebtedness remains manageable relative to the company’s capital base.
Negative Factors
Revenue Contraction
Declining revenue weakens the company’s operating base and can reduce purchasing leverage, scale benefits, and investment capacity. A sustained contraction would make margin recovery harder and increase dependence on cost controls rather than market expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate Leverage
Moderate leverage and a large equity base provide financial flexibility to absorb operating volatility and fund business needs. Although debt has risen from 2024, current indebtedness remains manageable relative to the company’s capital base.
Read all positive factors

Japan Medical Dynamic Marketing, Inc. (7600) vs. iShares MSCI Japan ETF (EWJ)

Japan Medical Dynamic Marketing, Inc. Business Overview & Revenue Model

Company Description
Japan Medical Dynamic Marketing, Inc. (JMDM) engages in the development, production, importation, and distribution of medical instruments throughout Japan and the United States. Its product portfolio features a variety of trauma devices, including...
How the Company Makes Money
null...

Japan Medical Dynamic Marketing, Inc. Financial Statement Overview

Summary
Fundamentals have weakened: revenue turned negative in 2026 and profitability compressed sharply (net margin ~1.1%, operating margin ~2.4%). The balance sheet remains reasonably leveraged (debt/equity ~0.23), but cash generation is a major concern with operating cash flow falling and free cash flow deeply negative in 2026, undermining earnings quality.
Income Statement
52
Neutral
Balance Sheet
63
Positive
Cash Flow
34
Negative
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue23.32B23.92B25.11B23.18B21.31B19.19B
Gross Profit12.00B12.74B15.65B14.76B13.99B12.99B
EBITDA1.62B2.19B1.40B3.27B3.35B4.21B
Net Income-220.55M263.14M-461.80M1.27B1.42B2.14B
Balance Sheet
Total Assets35.38B35.68B33.83B31.49B29.43B27.34B
Cash, Cash Equivalents and Short-Term Investments2.56B3.11B3.18B2.32B2.80B2.59B
Total Debt6.63B5.87B3.29B1.49B1.87B1.85B
Total Liabilities10.55B10.25B9.09B5.88B6.14B5.85B
Stockholders Equity24.81B25.40B24.68B25.51B23.16B21.39B
Cash Flow
Free Cash Flow0.00-1.75B-504.10M302.45M870.67M1.53B
Operating Cash Flow0.00205.55M1.05B2.10B2.19B3.11B
Investing Cash Flow0.00-2.00B-1.67B-1.80B-1.48B-1.75B
Financing Cash Flow0.001.65B1.49B-840.71M-514.78M-1.29B

Japan Medical Dynamic Marketing, Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price487.00
Price Trends
50DMA
892.08
Negative
100DMA
759.52
Positive
200DMA
629.91
Positive
Market Momentum
MACD
-12.13
Positive
RSI
43.60
Neutral
STOCH
16.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7600, the sentiment is Neutral. The current price of 487 is below the 20-day moving average (MA) of 883.65, below the 50-day MA of 892.08, and below the 200-day MA of 629.91, indicating a neutral trend. The MACD of -12.13 indicates Positive momentum. The RSI at 43.60 is Neutral, neither overbought nor oversold. The STOCH value of 16.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7600.

Japan Medical Dynamic Marketing, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
¥17.73B11.973.02%20.88%44.61%
63
Neutral
¥243.21B18.091.92%1.43%1.86%
58
Neutral
¥179.02B20.500.33%3.73%3.04%-19.26%
57
Neutral
¥75.63B21.882.28%2.94%57.05%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
54
Neutral
¥21.25B-100.963.12%-6.64%67.08%
49
Neutral
¥49.62B186.15-0.46%-8.42%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7600
Japan Medical Dynamic Marketing, Inc.
845.00
333.47
65.19%
JP:7779
CYBERDYNE
242.00
32.00
15.24%
JP:6523
PHC Holdings Corp.
1,486.00
485.56
48.54%
JP:4549
Eiken Chemical Co., Ltd.
2,359.00
-23.79
-1.00%
JP:6678
Techno Medica Co., Ltd.
2,115.00
175.60
9.05%
JP:6849
Nihon Kohden Corporation
1,523.50
-70.42
-4.42%

Japan Medical Dynamic Marketing, Inc. Corporate Events

Japan Medical Dynamic Marketing Swings to Quarterly Loss but Keeps Full-Year Dividend and Profit Outlook
Jul 30, 2026
Japan Medical Dynamic Marketing, Inc., a Tokyo-listed medical device supplier, reported weaker results for the quarter ended June 30, 2026, as net sales fell 10% year-on-year to ¥5,325 million and it swung to an operating loss of ¥526 mi...
Japan Medical Dynamic Marketing Details Relationship with Major Shareholder Mitsui Chemicals
Jun 22, 2026
Japan Medical Dynamic Marketing, Inc., a medical device-focused company listed on the TSE Prime Market, operates within the healthcare sector by developing and marketing medical devices while leveraging strategic alliances to strengthen its positi...
Japan Medical Dynamic Marketing Plans Shift to TSE Standard Market Amid Prime Compliance Shortfall
Jun 3, 2026
Japan Medical Dynamic Marketing has disclosed that, as of March 31, 2026, it no longer meets the Tokyo Stock Exchange Prime Market requirement for market capitalization of tradable shares, falling about ¥500 million short of the ¥10 bill...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 18, 2026